Last $7.26 USD
Change Today +0.2599 / 3.71%
Volume 1.3K
CORI On Other Exchanges
As of 8:10 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

corium international inc (CORI) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/18/14 - $8.49
52 Week Low
11/17/14 - $4.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

corium international inc (CORI) Related Businessweek News

No Related Businessweek News Found

corium international inc (CORI) Details

Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; Crest Whitestrips, which are a series of four products under the Advanced Vivid, Professional Effects, One Hour Express, and Flex-Fit brands for oral care. The company’s products under pipeline comprise AG200-15, a combination hormonal contraceptive patch, which delivers ethinyl estradiol and levonorgestrel hormones has completed a Phase III clinical trial; MicroCor hPTH(1-34), a transdermal system that has completed a Phase I clinical trial for the treatment of severe osteoporosis; and Corplex Tamsulosin that has completed a Phase I clinical trial for the treatment of benign prostatic hyperplasia. In addition, it is developing a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness; a generic transdermal product for the treatment of a urologic condition, as well as Donepezil and Memantine transdermal patches for the treatment of Alzheimer's disease; and Ropinerole and Pramipexole therapies for the treatment of Parkinson's disease. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Par Pharmaceutical, Inc.; Agile Therapeutics, Inc.; and others. The company was incorporated in 1995 and is headquartered in Menlo Park, California.

244 Employees
Last Reported Date: 12/15/14
Founded in 1995

corium international inc (CORI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $582.3K
Chief Financial Officer
Total Annual Compensation: $467.3K
Chief Technology Officer and Vice President o...
Total Annual Compensation: $392.2K
Compensation as of Fiscal Year 2014.

corium international inc (CORI) Key Developments

Corium International, Inc. Announces Board Changes

Corium International, Inc. announced the appointment of Ivan Gergel, M.D. to the Company's Board of Directors. Dr. Gergel currently serves as Senior Vice President, Drug Development & Chief Medical Officer of Nektar Therapeutics, and brings more than 25 years of pharmaceutical leadership and drug development experience to Corium's Board. Corium also announced that Daniel G. Welch has retired from the Board, effective December 4, 2014.

Corium Announces Closing of Expanded Term Loan Facility with CRG

Corium International, Inc. has closed an expanded term loan facility with CRG and certain of its affiliate funds. The revised Term Loan Agreement provides an additional $10 million to the company from CRG, which increases the aggregate principal loan amount to $45 million from the $35 million of outstanding principal provided for under the original agreement in July 2012. This revised term loan extends the maturity date of all debt to CRG from June 2017 to June 2019. Corium has drawn down the additional $10 million of principal available from this debt facility, primarily for use in supporting the advancement of its product development programs and proprietary technologies.

Corium International, Inc. Enters into Amended and Restated Term Loan Agreement

Corium International, Inc. entered into that certain Amended and Restated Term Loan Agreement with certain entities affiliated with Capital Royalty Group which amends and restates in its entirety the company's term loan agreement with CRG LP dated July 13, 2012. The Term Loan Agreement provides for an aggregate principal loan amount to the company by CRG LP of $45.0 million, which represents an increase of $10.0 million over the $35.0 million of outstanding principal provided for under the Original Agreement. In addition, the Term Loan Agreement extends the termination date under the Original Agreement from June 30, 2017 to June 30, 2019. The company intends to draw the additional $10.0 million of principal available pursuant to this Term Loan Agreement on or before December 15, 2014 (the Draw) and intends to use the Draw proceeds for working capital to support the advancement of its proprietary technologies and product development programs, as well as other general corporate purposes permitted under the Term Loan Agreement. The Draw is subject to customary closing conditions. Under the Term Loan Agreement, the company must pay interest quarterly in arrears at a simple annual rate of 15%, and will pay all outstanding principal in four equal quarterly payments beginning on September 30, 2018. In accordance with the Term Loan Agreement, the company may, on a quarterly basis, defer cash payment of that portion of the interest otherwise due equal to 3.5% of the then-outstanding principal until September 30, 2018, and may convert that deferred portion of the interest otherwise due into additional payment-in-kind notes, which become additional principal due under the terms of the Term Loan Agreement.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CORI:US $7.26 USD +0.2599

CORI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $164.02 USD -1.87
Actavis plc $279.12 USD +1.11
FUJIFILM Holdings Corp ¥3,781 JPY +15.50
Mylan Inc/PA $54.21 USD -0.23
Zogenix Inc $1.28 USD -0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation CORI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.1x
Price/Book 11.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORIUM INTERNATIONAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at